Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiple sclerosis risk sharing scheme: a costly failure.

× No keyword cloud information.

19 in total

1. Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom.

Authors: Trudy Owens; Nikos Evangelou; David K Whynes
Journal: Eur J Health Econ Date: 2012-01-24

Review 2. Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.

Authors: Bonny Parkinson; Catherine Sermet; Fiona Clement; Steffan Crausaz; Brian Godman; Sarah Garner; Moni Choudhury; Sallie-Anne Pearson; Rosalie Viney; Ruth Lopert; Adam G Elshaug
Journal: Pharmacoeconomics Date: 2015-09 Impact factor: 4.981

3. When do performance-based risk-sharing arrangements make sense?

Authors: Michael Drummond
Journal: Eur J Health Econ Date: 2015-07

4. NICE's cost-effectiveness range: should it be lowered?

Authors: J P Raftery
Journal: Pharmacoeconomics Date: 2014-07 Impact factor: 4.981

5. Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?

Authors: Livio Garattini; Alessandro Curto
Journal: Pharmacoeconomics Date: 2016-10 Impact factor: 4.981

6. Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.

Authors: Sergio Iannazzo; Ange-Christelle Iliza; Louise Perrault
Journal: Pharmacoeconomics Date: 2018-02 Impact factor: 4.981

7. Value-based pricing: incentive for innovation or zero net benefit?

Authors: Dyfrig A Hughes
Journal: Pharmacoeconomics Date: 2011-09 Impact factor: 4.981

8. Dynamic Learning of Patient Response Types: An Application to Treating Chronic Diseases.

Authors: Diana M Negoescu; Kostas Bimpikis; Margaret L Brandeau; Dan A Iancu
Journal: Manage Sci Date: 2017-08-21 Impact factor: 4.883

Review 9. Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.

Authors: Joel P Thompson; Amir Abdolahi; Katia Noyes
Journal: Pharmacoeconomics Date: 2013-06 Impact factor: 4.981

10. Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.

Authors: David Yamamoto; Jonathan D Campbell
Journal: Autoimmune Dis Date: 2012-12-06